Wednesday, June 14, 2023
Avertix Medical, Inc., previously known as Angel Medical Systems, Inc., has partnered with AdventHealth Orlando to make the Guardian™ System available to patients. Avertix is a company focused on improving the long-term management and outcomes of high-risk coronary disease in individuals who have survived one or more heart attacks. The Guardian™ System is the first FDA-approved implantable heart attack detection and warning system.
Developed by Avertix, the Guardian™ System is designed to detect acute coronary syndrome events, including silent and atypical symptomatic heart attacks, in real-time. It provides timely alerts to both patients and healthcare professionals, potentially saving lives. The system captures cardiac signals from inside the heart, ensuring enhanced accuracy and fidelity. By avoiding unnecessary emergency room visits and providing up-to-date patient data, the Guardian™ System supports personalized care and enables seamless monitoring of cardiovascular health outcomes using machine learning technology.
Dr. Usman Siddiqui, the medical director of electrophysiology at AdventHealth's hospitals in Celebration and Kissimmee, successfully conducted the first Guardian™ implant procedure in Central Florida at AdventHealth Orlando. As the top-rated hospital in Central Florida, AdventHealth Orlando is dedicated to advancing medical technology to provide exceptional care. Offering the Guardian™ System further demonstrates their commitment to innovative solutions for cardiac patients.
Cardiovascular diseases are the leading cause of death globally, according to the World Health Organization. In the United States, heart disease is the leading cause of death, with over 800,000 heart attacks occurring annually. Around 25% of heart attack survivors experience a second heart attack within five years of their initial one.
Avertix's President and CEO, Tim Moran, expressed pride in partnering with AdventHealth Orlando to introduce the Guardian™ System. This collaboration signifies their shared commitment to delivering purpose-driven and innovative healthcare solutions for cardiac care patients. The goal is to empower patients to live better lives without the fear of a potential second heart attack, while providing clinicians with the necessary tools for personalized and compassionate care.
On May 3, 2023, Avertix Medical, Inc. announced a definitive merger agreement with BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.). The completion of the transaction is expected to lead to the combined company's securities being listed on Nasdaq under the ticker symbol "AVRT."
https://www.globenewswire.com/news-release/2023/06/13/2687127/0/en/Avertix-s-Guardian-System-First-and-Only-FDA-Approved-Implantable-Heart-Attack-Detection-and-Warning-System-Now-Available-at-AdventHealth-Orlando.html
